Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sun Hee Lee
Institution:
Celltrion (South Korea)
Observed institution:
Celltrion (South Korea)
ORCID:
0000-0001-6865-9440
Observed ORCID:
0000-0001-6865-9440
OpenAlex ID:
A5087728944
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies
2025
·
Stefan Schreiber
, Jean-Frederic Colombel
, et al.
·
Inflammatory Bowel Diseases
·
17
PDF
Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
2022
·
Jihye Park
, Jae Hee Cheon
, et al.
·
Gut and Liver
·
8
PDF
Efficacy, Safety and Immunogenicity of Subcutaneous Infliximab (ct-p13 Sc) Monotherapy Versus Combination Therapy With Immunosuppressants – Post Hoc Analysis of Liberty-cd and Liberty-uc Study
2024
·
Stefan Schreiber
, Jean-Frederic Colombel
, et al.
·
Gastroenterology
·
3
PDF
Subcutaneous Infliximab (ct-p13 Sc) Dose Escalation as an Option for Managing the Loss of Response in Inflammatory Bowel Disease Post Hoc Analysis of Liberty-uc and Liberty-cd Study
2024
·
Silvio Danese
, Jean-Frederic Colombel
, et al.
·
Gastroenterology
PDF
Efficacy, Safety and Immunogenicity of Subcutaneous Infliximab (ct-p13 Sc) Monotherapy Versus Combination Therapy With Immunosuppressants – Post Hoc Analysis of Liberty-cd and Liberty-uc Study
2024
·
Stefan Schreiber
, Jean-Frederic Colombel
, et al.
·
Inflammatory Bowel Diseases
PDF
Subcutaneous Infliximab (ct-p13 Sc) Dose Escalation as an Option for Managing the Loss of Response in Inflammatory Bowel Disease Post Hoc Analysis of Liberty-uc and Liberty-cd Study
2024
·
Silvio Danese
, Jean-Frederic Colombel
, et al.
·
Inflammatory Bowel Diseases
PDF
Show more works
View as search
Works count:
6
Citation count:
28
H-index:
3
I10-index:
1
Year
Topic
Type
